Clinical Trials Not Recruiting for Mesothelioma

Clinical Trials Not Recruiting for Mesothelioma Active Trials

Clinical trials for mesothelioma are critical for discovering new treatments. They have a predetermined limit on the number of participants. Once this limit is reached, the trial stops accepting new patients but continues with the existing participants. These trials are essential for gaining insights into the effectiveness of new therapies for mesothelioma.

Current State of Mesothelioma Clinical Trials

Ongoing clinical trials in mesothelioma are crucial for exploring innovative treatments. When these studies reach their full enrollment capacity, they transition into a crucial phase of treatment and observation of the enrolled patients. This phase is essential for gathering valuable data on the effectiveness and safety of the new therapies being evaluated.

One notable example is the CheckMate 743 trial conducted in 2020. This trial was significant in assessing the effectiveness of combining two immunotherapy drugs against traditional chemotherapy in mesothelioma treatment. The trial compared the outcomes of patients treated with the combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) to those receiving standard chemotherapy. The results showed that the patients receiving the immunotherapy combination had a median survival time that was approximately four months longer than those on chemotherapy.

These findings led to the U.S. Food and Drug Administration (FDA) approval of nivolumab and ipilimumab for the treatment of inoperable pleural mesothelioma. This approval is a significant advancement in mesothelioma treatment, providing new therapeutic options for patients facing this challenging disease.

Ongoing Clinical Trials Not Recruiting Mesothelioma Patients

  1. Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Previously Treated in Bayer-sponsored Studies
    • Conditions: Various Solid Tumors
    • Last Updated: January 27, 2022
    • Status: Active, not recruiting
    • Locations: Chicago, IL. Bethesda, MD. Nashville, TN. Dallas, TX.
  2. Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy for Stage I-III Pleural Malignant Mesothelioma
    • Conditions: Mesothelioma, Lung Neoplasms
    • Last Updated: January 27, 2022
    • Status: Active, not recruiting
    • Locations: Various locations across the United States
  3. MEDI4736 or MEDI4736 + Tremelimumab Treatment for Surgically Resectable Malignant Pleural Mesothelioma
    • Conditions: Mesothelioma, Malignant
    • Last Updated: January 25, 2022
    • Status: Active, not recruiting
    • Locations: Houston, TX.
  4. Phase 2/3 Study in Subjects With Malignant Pleural Mesothelioma to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
    • Conditions: Mesothelioma, Malignant
    • Last Updated: January 24, 2022
    • Status: Active, not recruiting
    • Locations: Various locations across the United States
  5. Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate for Malignant Pleural Mesothelioma
    • Conditions: Mesothelioma, Lung Neoplasms
    • Last Updated: January 22, 2022
    • Status: Active, not recruiting
    • Locations: Various locations across the United States
  6. PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
    • Conditions: Various Solid Tumors
    • Last Updated: January 21, 2022
    • Status: Active, not recruiting
    • Locations: Various locations across the United States
  7. Intra-pleural Administration of GL-ONC1 in Patients With Malignant Pleural Effusion (Various Types)
    • Conditions: Vaccinia, Mesothelioma, Pleural Effusion, Malignant
    • Last Updated: January 19, 2022
    • Status: Active, not recruiting
    • Locations: New York, NY.
  8. Atezolizumab and Bevacizumab Treatment for Rare Solid Tumors
    • Conditions: Various Rare Solid Tumors
    • Last Updated: January 18, 2022
    • Status: Active, not recruiting
    • Locations: Houston, TX.
  9. Methoxyamine, Cisplatin, and Pemetrexed Disodium for Advanced Solid Tumors or Mesothelioma
    • Conditions: Various Solid Tumors, Mesothelioma
    • Last Updated: January 15, 2022
    • Status: Active, not recruiting
    • Locations: Various locations across the United States
  10. First-in-human Study of BAY2287411 Injection in Patients With Tumors Expressing Mesothelin
    • Conditions: Mesothelioma, Malignant
    • Last Updated: January 11, 2022
    • Status: Active, not recruiting
    • Locations: Bethesda, MD. Houston, TX.
  11. The Transitions Project: Supporting Adults in Cancer Treatment to Surveillance Shift
    • Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Mesothelioma, Mesothelioma, Malignant
    • Last Updated: January 11, 2022
    • Status: Active, not recruiting
    • Location: Boston, MA.
  12. Pembrolizumab Treatment for Advanced Malignant Pleural Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: January 6, 2022
    • Status: Active, not recruiting
    • Locations: Alessandria, Alabama. Catania, Connecticut.
  13. LY3023414 Study in Participants With Advanced Cancer
    • Conditions: Neoplasms, Mesothelioma, Mesothelioma, Malignant
    • Last Updated: January 5, 2022
    • Status: Active, not recruiting
    • Locations: Los Angeles, CA. New York, NY. Oklahoma City, OK. Philadelphia, PA. Nashville, TN. Nashville, TN.
  14. Niraparib Trial in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
    • Conditions: Neoplasms, Melanoma, Carcinoma, Renal Cell, Mesothelioma, Mesothelioma, Malignant, Cholangiocarcinoma
    • Last Updated: December 23, 2021
    • Status: Active, not recruiting
    • Locations: Gainesville, FL. Miami, FL. Orlando, FL.
  15. Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy for Advanced/Metastatic Solid Tumors
    • Conditions: Carcinoma, Renal Cell, Mesothelioma
    • Last Updated: December 22, 2021
    • Status: Active, not recruiting
    • Locations: Mobile, AL. Scottsdale, AZ. Tucson, AZ. Baltimore, MD. Boston, MA. Boston, MA. Detroit, MI. Nashville, TN. Nashville, TN. Houston, TX. Houston, TX. San Antonio, TX.
  16. Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
    • Conditions: Neoplasms
    • Last Updated: December 21, 2021
    • Status: Active, not recruiting
    • Locations: Los Angeles, CA. Gainesville, FL. Detroit, MI. Saint Louis, MO. Hackensack, NJ. New York, NY. Chapel Hill, NC. Oklahoma City, OK. Portland, OR. Philadelphia, PA. Pittsburgh, PA. Nashville, TN. Dallas, TX. Houston, TX. Seattle, WA.
  17. Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
    • Conditions: Lymphoma, Sarcoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Sarcoma, Synovial, Carcinoma, Medullary
    • Last Updated: December 8, 2021
    • Status: Active, not recruiting
    • Locations: Tucson, AZ. Tampa, FL. Ann Arbor, MI. New York, NY. New York, NY.
  18. Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: November 30, 2021
    • Status: Active, not recruiting
    • Location: Tampa, FL.
  19. Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: November 10, 2021
    • Status: Active, not recruiting
    • Locations: La Jolla, CA. Los Angeles, CA. Stanford, CA. Aurora, CO. Miami, FL. Atlanta, GA. Chicago, IL. Evanston, IL. Baltimore, MD. Ann Arbor, MI. Saint Louis Park, MN. Saint Louis, MO. New Brunswick, NJ. New York, NY. Philadelphia, PA. Pittsburgh, PA. Dallas, TX. Fairfax, VA. Seattle, WA. Wauwatosa, WI.
  20. CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: November 6, 2021
    • Status: Active, not recruiting
  21. Autologous T Cells Targeting Mesothelin for Malignant Pleural Disease
    • Conditions: Mesothelioma, Pleural Diseases
    • Last Updated: October 29, 2021
    • Status: Active, not recruiting
    • Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY.
  22. rAd-IFN, Celecoxib & Gemcitabine for Malignant Pleural Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: October 25, 2021
    • Status: Active, not recruiting
    • Locations: Los Angeles, CA. San Francisco, CA. Tampa, FL. Kansas City, KS. Baltimore, MD. Baltimore, MD. Minneapolis, MN. Rochester, MN. New York, NY. Philadelphia, PA. Dallas, TX.
  23. Tremelimumab vs. Placebo in Unresectable Malignant Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
    • Last Updated: October 20, 2021
    • Status: Active, not recruiting
    • Locations: Scottsdale, AZ. La Jolla, CA. Los Angeles, CA. San Francisco, CA. Santa Monica, CA. New Haven, CT. Newark, DE. Tampa, FL. Augusta, GA. Chicago, IL. Peoria, IL. Minneapolis, MN. New York, NY. Rochester, NY. Durham, NC. Canton, OH. Philadelphia, PA. Dallas, TX. Houston, TX.
  24. Phase I Trial of HIPEC With Nal-irinotecan
    • Conditions: Mesothelioma, Adenocarcinoma, Mucinous, Cystadenocarcinoma, Pseudomyxoma Peritonei
    • Last Updated: October 19, 2021
    • Status: Active, not recruiting
    • Locations: Lexington, KY. Stony Brook, NY.
  25. Pembrolizumab for Malignant Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
    • Last Updated: October 8, 2021
    • Status: Active, not recruiting
    • Location: Chicago, IL.
  26. Comparative Study: Regional vs. General Anesthesia in Thoracoscopes
    • Conditions: Empyema, Empyema, Pleural, Mesothelioma, Pleural Effusion, Malignant, Pleural Neoplasms, Pleural Effusion, Pulmonary Atelectasis, Pneumothorax, Pleural Diseases, Hemothorax, Pericardial Effusion, Lymphadenopathy
    • Last Updated: September 30, 2021
    • Status: Active, not recruiting
  27. LMB-100 and Tofacitinib for Mesothelin Expressing Solid Tumors
    • Conditions: Adenocarcinoma, Mesothelioma, Cholangiocarcinoma
    • Last Updated: September 29, 2021
    • Status: Active, not recruiting
    • Location: Bethesda, MD.
  28. Intrapleural Cryotherapy for Malignant Pleural Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: September 14, 2021
    • Status: Active, not recruiting
    • Location: Rochester, MN.
  29. Dose-Escalation Study of IPI-549
    • Conditions: Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Mesothelioma, Mesothelioma, Malignant, Neoplasms, Squamous Cell, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Adrenocortical Carcinoma
    • Last Updated: September 13, 2021
    • Status: Active, not recruiting
    • Locations: San Diego, CA. Santa Monica, CA. Port Saint Lucie, FL. Atlanta, GA. Boston, MA. Hackensack, NJ. New York, NY. Houston, TX. San Antonio, TX.
  30. Pevonedistat Alone and in Combination With Chemotherapy for Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: September 10, 2021
    • Status: Active, not recruiting
    • Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Rockville Centre, NY. Uniondale, NY.
  31. Pembrolizumab Combination Study for Advanced Malignant Pleural Mesothelioma (MK-3475-A17)
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: September 8, 2021
    • Status: Active, not recruiting
  32. Rebastinib (DCC-2036) Combination Study for Advanced Solid Tumors
    • Conditions: Neoplasms
    • Last Updated: August 10, 2021
    • Status: Active, not recruiting
    • Locations: San Francisco, CA. Santa Monica, CA. Chicago, IL. Kansas City, KS. Charlotte, NC. Columbus, OH. Nashville, TN. Houston, TX. San Antonio, TX.
  33. ABBV-368 Safety and Pharmacokinetics Study for Locally Advanced or Metastatic Solid Tumors
    • Conditions: Neoplasms
    • Last Updated: July 29, 2021
    • Status: Active, not recruiting
    • Locations: La Jolla, CA. Sacramento, CA. Stanford, CA. New Haven, CT. Huntersville, NC. Greenville, SC. Dallas, TX. San Antonio, TX. Charlottesville, VA. Fairfax, VA.
  34. Phase II Trial of Alisertib (MLN8237) for Salvage Malignant Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: June 15, 2021
    • Status: Active, not recruiting
    • Location: Houston, TX.
  35. Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Malignant Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms
    • Last Updated: June 11, 2021
    • Status: Active, not recruiting
    • Locations: Basking Ridge, NJ. Middletown, NJ. Commack, NY. Harrison, NY. New York, NY. Rockville Centre, NY. Uniondale, NY.
  36. Psychosocial Needs and Online Support for Mesothelioma Patients
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: May 10, 2021
    • Status: Active, not recruiting
    • Location: New York, NY.
  37. Budigalimab (ABBV-181) Study for Advanced Solid Tumors
    • Conditions: Neoplasms
    • Last Updated: May 3, 2021
    • Status: Active, not recruiting
    • Locations: La Jolla, CA. Chicago, IL. Huntersville, NC. San Antonio, TX. Fairfax, VA.
  38. TILs & Low-Dose IL-2 Therapy for Pleural Mesothelioma Patients
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: April 11, 2021
    • Status: Active, not recruiting
  39. Nivolumab and Ipilimumab vs. Pemetrexed and Cisplatin or Carboplatin for First-Line Therapy in Unresectable Pleural Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: March 24, 2021
    • Status: Active, not recruiting
    • Locations: San Francisco, CA. New Haven, CT. Tampa, FL. Chicago, IL. Baltimore, MD. Detroit, MI. Grand Rapids, MI. Rochester, MN. New York, NY. Cleveland, OH. Jefferson Hills, PA. Philadelphia, PA. Houston, TX. Morgantown, WV.
  40. Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma
    • Conditions: Lung Neoplasms, Mesothelioma, Mesothelioma, Malignant
    • Last Updated: March 4, 2021
    • Status: Active, not recruiting
  41. PembROlizuMab Immunotherapy vs. Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: February 8, 2021
    • Status: Active, not recruiting
  42. Randomized Phase II Open-label Study With ONCOS-102 and Pemetrexed/Cisplatin for Unresectable Malignant Pleural Mesothelioma
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: October 6, 2020
    • Status: Active, not recruiting
  43. Double Blind, Placebo-Controlled Phase II Study of Gemcitabine With or Without Ramucirumab for Second-Line Treatment of MPM
    • Conditions: Mesothelioma, Mesothelioma, Malignant
    • Last Updated: July 29, 2020
    • Status: Active, not recruiting
  44. Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
    • Conditions: Mesothelioma
    • Last Updated: May 9, 2019
    • Status: Active, not recruiting
    • Locations: New York, NY. Houston, TX.